Investigating the connection between diabetes drugs and weight loss in patients with type II diabetes mellitus: A prospective cohort study

<h2>Abstract:</h2><h3>Introduction</h3> Diabetes mellitus is the most common of the endocrine disorders. It is a chronic condition, characterized by hyperglycemia and due to impaired insulin secretion with or without insulin resistance. American Diabetes Association (ADA) defines diabetes mellitus as a group of metabolic diseases characterized by inappropriate hyperglycemia resulting from defects in insulin secretion, insulin action, or both. <h3>Aim</h3> To investigate the correlation between different diabetic medications and weight fluctuations in individuals diagnosed with Type 2 Diabetes Mellitus (T2DM) through a prospective cohort study. <h3>Methods</h3> A Prospective Cohort study was conducted among type 2 diabetes mellitus patients. 410 volunteer patients were participated in our study. Out of them 18 members were excluded and 392 were included based on our study criteria. <h3>Results</h3> In this study we explored the relationship between Diabetic medications and type 2 diabetes mellitus patients. Our study shows that Metformin 500 mg and Voglibose 0.2 mg has significant association with GRBS Levels and Metformin 500 mg has significant association with weight loss. We also observed slight increase in weight in case of Glimepiride 1mg & Glimepiride 2 mg but which is not clinically significant. Slight weight loss is observed in Sitagliptin 100 mg, Teneligliptin 20 mg, Vildagliptin 50 mg and Voglibose 0.2 mg but out of which those are not clinically significant. <h3>Conclusion</h3> Our findings underscore the importance of individualized medication management strategies tailored to optimize both glycaemic control and weight outcomes in type 2 diabetes mellitus management. Continued research in this area is essential to refine treatment guidelines and improve clinical outcomes for type 2 diabetes mellitus patients.